Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Aug 15, 2026 to Apr 22, 2020
    • Study completion pushed from Aug 15, 2026 to Apr 15, 2027
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 1 of 2 entries
  2. Primary and study completion dates: Aug 15, 2025 to Aug 15, 2026v14
  3. Primary and study completion dates: Dec 31, 2024 to Aug 15, 2025v13
  4. Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024v12
  5. Re-verified, no change to tracked fieldsv11
Show 9 earlier versionsHide 9 earlier versions
  1. Primary completion date: Dec 31, 2022 to Dec 31, 2023v10
  2. Primary completion date: Dec 31, 2021 to Dec 31, 2022v9 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 60 to confirmed 22
    • Study completion date: Jan 31, 2022 to Dec 31, 2023
    • Site details revised at 2 of 2 sites
  3. Trial status: Suspended to Recruiting
    • Primary completion date: Dec 31, 2020 to Dec 31, 2021
    • Study completion date: Jan 31, 2021 to Jan 31, 2022
    • Site details revised at 2 of 2 sites
    v8
  4. Primary completion date: Jan 31, 2020 to Dec 31, 2020v7
  5. Trial status: Recruiting to Suspended Sponsor's reason: PI decsion
    • Site details revised at 2 of 2 sites
    v6
  6. Study sites: 1 to 2v5
  7. Site contact updatedv4
  8. Site contact updatedv3
  9. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Primary endpoint revised
    • Primary completion date: Jan 2020 to Jan 31, 2020
    • Study completion date: Jan 31, 2021
    • Start date: Jan 2017 to Feb 21, 2017
    • Site details revised
    • Collaborators: 1 to 2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I study studies the side effects and best dose of venetoclax and lenalidomide when given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or not responding to treatment. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving obinutuzumab, venetoclax, and lenalidomide may work better in treating patients with B-cell non-Hodgkin lymphoma.
Trial Details
NCT Number NCT02992522
Lead Sponsor Beth Christian
Collaborators: Celgene, Genentech, Inc.
Conditions
(from sponsor)		 B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma +5 more
Related terms Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov